Loading...
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following fir...
Na minha lista:
| Udgivet i: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Health
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8078251/ https://ncbi.nlm.nih.gov/pubmed/33683919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02212 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|